Through genomic and transcriptional profiling of tumor tissue and genomic profiling of plasma samples obtained from the BEACON CRC study cohort, we characterized the molecular landscape of BRAF-V600E-mutant mCRC treated with Enco+Cetux±Bini versus Cetux plus chemotherapy to understand the evolving biology of these tumors on treatment. The gene discussed is BRAF; the disease is neoplasm.